Your search for osteoporosis returned 6 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove
Debra Hughes, MS remove
Older than 2 years remove

Your search for osteoporosis returned 6 results

Sort Results:

Relevant Recent
ACR/ARHP Annual Meeting 2015

Low Incidence of Jaw Osteonecrosis With Prolia, Bisphosphonate Tx

Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, according to data presented by Fei Xue, MD, Center for Observational Research, Amgen Inc, at the 2015 ACR/ARHP Annual Meeting.
ACR/ARHP Annual Meeting 2015

Surprising Link Between Sodium Intake and Postmenopausal Hip Fracture Risk

Higher levels of sodium intake are associated with a lower risk of hip fractures among postmenopausal women, but adherence to sodium-intake recommendations for cardiovascular health does not affect bone mineral density (BMD), according to findings from the Women's Health Initiative (WHI) reported at the 2015 ACR/ARHP Annual Meeting.
PAINWeek 2014

Easing the Transition to ICD-10-CM Implementation

Marvel J. Hammer, RN, CPC, CCS-P, ACS-PM, CPCO, of MJH Consulting, Denver, Colorado provided PAINWeek attendees a detailed overview of the differences between ICD-9-CM and ICD-10-CM codes for many diagnoses currently encountered in pain management and a list of steps to ease the transition to ICD-10-CM.
PainWeek 2013

When Women Present with Musculoskeletal Pain, Assess Hormonal Factors

Anatomic variability in women predisposes them to specific musculoskeletal conditions, which differ during life stages. "There are important differences between the sexes for many clinical pain disorders which may be explained, at least in part, by hormonal mechanisms," said Colleen M. Fitzgerald, MD, MS at PAINWeek 2013.
ASH 2011

Risedronate Reduces Some Bone Loss in Patients with ALL/LL Receiving High-Dose Corticosteroids

Adult patients with acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LL) treated with the Hyper-CVAD regimen are at very high risk for rapid bone loss from the high-dose corticosteroid early in their treatment, the first study to show such a loss concluded during at the 53rd American Society of Hematology Annual Meeting and Exposition.